Balchem (NASDAQ:BCPC) Shares Down 84.5% - Should You Sell?

Balchem Corporation (NASDAQ:BCPC - Get Free Report) dropped 84.5% on Friday . The company traded as low as $151.70 and last traded at $24.57. Approximately 81,292 shares traded hands during trading, a decline of 43% from the average daily volume of 143,026 shares. The stock had previously closed at $158.37.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. HC Wainwright set a $180.00 price objective on Balchem and gave the company a "buy" rating in a report on Monday, April 28th. Wall Street Zen downgraded Balchem from a "buy" rating to a "hold" rating in a research note on Wednesday, May 21st.

Balchem Price Performance

The firm has a market cap of $5.03 billion, a PE ratio of 5.90, a price-to-earnings-growth ratio of 3.30 and a beta of 0.89. The stock has a 50 day moving average price of $163.15 and a two-hundred day moving average price of $162.67. The company has a quick ratio of 1.40, a current ratio of 2.44 and a debt-to-equity ratio of 0.18.

Balchem (NASDAQ:BCPC - Get Free Report) last released its earnings results on Thursday, April 24th. The basic materials company reported $1.22 EPS for the quarter, missing analysts' consensus estimates of $1.25 by ($0.03). Balchem had a return on equity of 12.01% and a net margin of 14.16%. The firm had revenue of $250.52 million for the quarter, compared to the consensus estimate of $245.70 million. During the same period in the prior year, the business earned $1.03 EPS. The company's quarterly revenue was up 4.5% on a year-over-year basis. As a group, equities analysts expect that Balchem Corporation will post 4.64 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BCPC. Norges Bank bought a new position in Balchem during the fourth quarter worth $70,165,000. Nuveen LLC bought a new stake in shares of Balchem during the 1st quarter valued at about $47,214,000. GAMMA Investing LLC grew its position in Balchem by 20,231.2% in the 1st quarter. GAMMA Investing LLC now owns 177,288 shares of the basic materials company's stock valued at $29,430,000 after acquiring an additional 176,416 shares during the last quarter. Millennium Management LLC raised its stake in shares of Balchem by 660.5% in the first quarter. Millennium Management LLC now owns 195,525 shares of the basic materials company's stock worth $32,457,000 after purchasing an additional 169,816 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Balchem by 53.6% during the first quarter. Goldman Sachs Group Inc. now owns 246,883 shares of the basic materials company's stock worth $40,983,000 after buying an additional 86,132 shares in the last quarter. Institutional investors and hedge funds own 87.91% of the company's stock.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.